Two sides to colon cancer: mice mimic human anatomical region disparity in colon cancer development and progression

Abstract

Aim: Strong evidence reveals important differences between cancers in the proximal vs. distal colon. Animal models of metastatic colon cancer are available but with varying degrees of reproducibility and several important limitations. We explored whether there were regional differences in the location of murine colon cancers and assessed the utility of murine models to explore the biological basis for such differences.

Methods: We re-analyzed data from our previous studies to assess the regional distribution of murine colon cancer. In survival surgery experiments, we injected HT-29 human colon cancer cells into the wall of the cecum or distal colon of Nu(NCr)-Foxn1^nu or NOD.Cg-Prkdc^scidIl2rg^Tim1Wji/SzJ mice and compared the development of primary tumors and metastases.

Results: Within 7-17 weeks after intramural cecal injection of HT-29 cells, eight mice failed to develop solid primary tumors or metastases. In contrast, within four weeks after cell injection into the distal colon, 13 mice developed metastases - 12 mice developed subcutaneous metastases; of these, four developed liver metastases and one developed both liver and lung metastases. One mouse developed liver metastases only. Histological examination confirmed these lesions were adenocarcinomas.

Conclusion: Our findings reveal the preferential growth of murine colon neoplasia and invasive human orthotopic xenografts in the distal mouse colon. The new approach of injecting cells into the distal colon wall results in a pattern of colon cancer development that closely mimics the progression of metastatic colon cancer in humans. This novel model of colon neoplasia has great potential for exploring anatomical differences in colon cancer and testing novel therapeutics.

Keywords

Colorectal cancer / orthotopic tumor model / mouse model / HT-29 cells / colon

References

[1] Lee WY,Ham SK,Cho YB.Comparison of colorectal cancer in differentially established liver metastasis models.Anticancer Res2014;34:3321-8

[2] Iacopetta B.Are there two sides to colorectal cancer?.Int J Cancer2002;101:403-8

[3] Sugai T,Jiao YF,Takeda Y,Nakamura S.Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas.J Mol Diagn2006;8:193-201 PMCID:PMC1867579

[4] Azzoni C,Campanini N,Bader G,Salvemini C,Di Mauro D,Roncoroni L,Sarli L.Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis.Int J Colorectal Dis2007;22:115-26

[5] Watanabe T,Toda E,Kanazawa T,Tanaka J,Konishi T,Sugimoto Y,Sasaki S,Nagawa H.Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers.Cancer Res2006;66:9804-8

[6] Benedix F,Meyer F,Gastinger I,Group CRCPTS.Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival.Dis Colon Rectum2010;53:57-64

[7] Wang C,Raldow A.Differences in cancer-specific mortality of right- versus left-sided colon adenocarcinoma: a surveillance, epidemiology, and end results database analysis.JCO Clinical Cancer Informatics2017;1:1-9

[8] Meguid RA,Wolfgang CL,Ahuja N.Is there a difference in survival between right- versus left-sided colon cancers?.Ann Surg Oncol2008;15:2388-94 PMCID:PMC3072702

[9] Weiss JM,O'Connor ES,LoConte N,Smith MA.Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data.J Clin Oncol2011;29:4401-9 PMCID:PMC3221523

[10] Lim DR,Kim T.Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection: which side is better outcome?.Medicine (Baltimore)2017;96:e8241 PMCID:PMC5662378

[11] Polakis P.The oncogenic activation of beta-catenin.Curr Opin Genet Dev1999;9:15-21

[12] Terracina KP,Huang WC,Yamada A,Takabe K.Development of a metastatic murine colon cancer model.J Surg Res2015;199:106-14 PMCID:PMC4604007

[13] Golovko D,Yilmaz Ö.Colorectal cancer models for novel drug discovery.Expert Opin Drug Discov2015;10:1217-29 PMCID:PMC4872297

[14] Flatmark K,Martinsen M,Fodstad Ø.Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice.Eur J Cancer2004;40:1593-8

[15] Cheng K,Felton J,Drachenberg CB,Zhan M,Guo GL,Raufman JP.Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice.Oncotarget2018;9:25572-85 PMCID:PMC5986650

[16] Cheng K,Khurana S,Drachenberg CB,Shah N.Divergent effects of muscarinic receptor subtype gene ablation on murine colon tumorigenesis reveals association of M3R and zinc finger protein 277 expression in colon neoplasia.Mol Cancer2014;13:77 PMCID:PMC4021221

[17] Raufman JP,Xie G,Gao XM,Shah N,Heath J,Khurana S.Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice.Carcinogenesis2011;32:1396-402 PMCID:PMC3165126

[18] Raufman JP,Rao A,Heath J,Hu S,Polli JE.Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids.Carcinogenesis2015;36:1193-200 PMCID:PMC4612337

[19] Raufman JP,Shah N,Shant J,Xie G,Cheng K.Genetic ablation of M3 muscarinic receptors attenuates murine colon epithelial cell proliferation and neoplasia.Cancer Res2008;68:3573-8 PMCID:PMC2577901

[20] Dougherty U,Taylor I,Tekin U,Aluri L,Cerda S,Delgado J,Zhu H,Threadgill D,Bissonnette M.Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2.Clin Cancer Res2009;15:6780-9 PMCID:PMC2785126

[21] Boivin GP,Yang K,Pretlow TP,Besselsen DG,Doetschman T,Pitot HC,Itzkowitz SH,Coffey RJ.Pathology of mouse models of intestinal cancer: consensus report and recommendations.Gastroenterology2003;124:762-77

[22] Céspedes MV,García-Cabezas MA,Boluda A,Sancho FJ,Lacal JC.Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites.Am J Pathol2007;170:1077-85 PMCID:PMC1864873

[23] Hackl C,Francia G,Xu P.Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.Gut2013;62:259-71 PMCID:PMC3553490

[24] Hite N,Hellmers L,Miller PE,Li L.An optimal orthotopic mouse model for human colorectal cancer primary tumor growth and spontaneous metastasis.Dis Colon Rectum2018;61:698-705

[25] Stintzing S,Gibbs P,Lenz HJ.Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.Eur J Cancer2017;84:69-80

[26] Leijssen LGJ,Kunitake H,Berger DL.Pathologic factors are more important than tumor location in long-term survival in colon cancer.Int J Colorectal Dis2018;33:709-17

[27] Kopp R,Mutschler E,Tacke R.Human HT-29 colon carcinoma cells contain muscarinic M3 receptors coupled to phosphoinositide metabolism.Eur J Pharmacol1989;172:397-405

[28] Belo A,Chahdi A,Xie G,Raufman JP.Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion.Am J Physiol Gastrointest Liver Physiol2011;300:G749-60 PMCID:PMC3094147

[29] Raufman JP,Saxena N,Belo A,Xie G.Muscarinic receptor agonists stimulate matrix metalloproteinase 1-dependent invasion of human colon cancer cells.Biochem Biophys Res Commun2011;415:319-24 PMCID:PMC3221914

[30] Sanmamed MF,Melero I.Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.Ann Oncol2016;27:1190-8